Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 9 of 6351
-
Can a single injection reprogram immune cells to fight cancer?
Cure Recruiting nowThis is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with…
Phase 1 • Sponsor: Ruijin Hospital • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a gene therapy restore natural hearing after cochlear implants?
Cure OngoingThis study will evaluate the safety, tolerability, and efficacy of EA0010 injection in patients with OTOF-related hearing loss who have already undergone cochlear implantation. Conventional gene therapy generally excludes cochlear implant recipients, based on the concern that the…
Sponsor: Shanghai EmayGene Technology Co., Ltd • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
New drug could help babies with SMA walk and sit normally
Disease control Recruiting nowIn this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have been diagnosed with SMA through genetic testing but have not yet started showing …
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Gene editing trial hopes to fix duchenne muscular dystrophy at its source
Disease control Recruiting nowThe purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55. Given the limitations of existing therapeutic strategies, PBGENE-DMD represents a nov…
Phase 1/2 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hope for kids with rare paralysis: gene therapy trial launches
Disease control Recruiting nowPhase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Phase 3 • Sponsor: Elpida Therapeutics SPC • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can reprogrammed immune cells silence lupus? a small trial aims to find out.
Cure By invitation onlySystemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease. In the treatment of SLE today, glucocorticosteroid hormones, cytost…
Sponsor: N.N. Alexandrov National Cancer Centre • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Could a stem cell shot free liver transplant patients from a lifetime of pills?
Disease control Recruiting nowThis clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed…
Phase 1/2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Radical new schedule aims to cure High-Risk ewing sarcoma
Cure Recruiting nowThis single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics a…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Cure
Last updated Aug 30, 2026 00:00 UTC
-
Gene editing could cure sickle cell and thalassemia in new trial
Cure Recruiting nowA promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease. In gene therapy, the investigators introduce new genetic…
Phase 1 • Sponsor: Daniel Bauer • Aim: Cure
Last updated Jun 27, 2026 09:01 UTC
-
Pig kidney transplant trial offers new hope for kidney patients
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transpl…
Phase 1/2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can a single gene injection preserve sight in inherited blindness?
Cure Recruiting nowThis open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.
Phase 1/2 • Sponsor: SparingVision • Aim: Cure
Last updated Sep 09, 2026 15:00 UTC
-
One-Time gene infusion aims to fight duchenne muscular dystrophy
Disease control Recruiting nowThe study will evaluate the tolerability, safety and efficacy of gene therapy product in boys with Duchenne muscular dystrophy (DMD). In Phase I the participants will be included in two sequential dose cohorts with increasing doses of the investigational product. Based on the res…
Phase 1/2 • Sponsor: AO GENERIUM • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a shot for moms shield babies from deadly RSV?
Vaccine Recruiting nowRespiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too early and those born with heart and lung problems. It …
Phase 3 • Sponsor: University of Witwatersrand, South Africa • Aim: Vaccine
Last updated Jun 27, 2026 12:35 UTC
-
Gene-Editing breakthrough aims to stop sickle cell pain
Disease control Recruiting nowThis is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SC…
Phase 1/2 • Sponsor: Mark Walters, MD • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Yearly HIV prevention shot could change the game
Prevention OngoingThe goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophy…
Phase 3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Aug 30, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart a deadly leukemia?
Cure Recruiting nowThis is a Phase I/II study evaluating safety and efficacy of proteasome inhibitor (bortezomib) in combination with CPX-351 (liposomal daunorubicin and cytarabine) for the treatment of newly-diagnosed TP53-mutated acute myeloid leukemia (TP53m AML). The primary endpoint of the st…
Phase 1/2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowDNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict the cancer signal origin (CSO) from a single fluid…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Mind over matter: can a brain implant restore hand control?
Disease control CompletedTo evaluate the safety and efficacy of a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO in patients with tetraplegia and to provide a basis for product registration. Through brain-computer interface alternative technology, patients can control …
Sponsor: Neuracle Medical Technology(Shanghai) Co.,Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug aims to stop rare genetic disease before it strikes
Prevention Recruiting nowTransthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR…
Phase 3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
One shot, six months of malaria shield? a new trial tests a powerful antibody in children
Prevention OngoingBackground and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and de…
Phase 3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC